Active patent strategy
A key element of CombiGene’s strategy is to protect its intellectual property rights with strong patents. CombiGene strives to maximize protection for its innovations by obtaining patent protection in all key global markets, including the US and Europe.
As a rule, CombiGene works within the Patent Cooperation Treaty (PCT) framework. PCT is an international agreement that allows companies to seek patent protection internationally for their inventions, covering approximately 150 countries with one single application.
CombiGene currently holds patents in two families for the epilepsy project CG01. The first family covers approximately ten countries, and within the second family, CombiGene has applied for patent protection in approximately ten countries, and has so far been granted patent protection in two countries, the U.S. and Russia.
Within the lipodystrophy project CGT2, CombiGene has submitted a PCT application, following an initial priority patent application with the UK Patent Office.
1st family – Use of nucleic acid sequences for the treatment of neurological and psychiatric diseases, vectors and compositions
|Patent family||Patent application no||Granted||Date of Priority||Expires|
|1 - NPY||07769040.2||SE, PL, NL, IT, GB, FR, ES, DE, CH, BE||2006-07-04||2027-07-04|
|1 – NPY||12/308,959||US||2006-07-04||2029-01-30|
2nd family – Protection of CG01 vector
|Country||Patent application no||Status||Date of Priority||Day of Filing||Expires|
|The U.S.||16/070,443||Granted||2016-02-12||2018-07-16||2037-02-10 + 315 days|
|Patent pending in Australia, Canada, European Patent Office, India, Japan, China, and South Korea.|
CGT2 patent applications
|Organization||Patent application no||Status||Date of Priority||Day of Filing||Expires|
|UK Patent Office||2013194.2||Expired||2020-08-24||2020-08-24||-|
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.